I am a neurobiologist working on the pathogenesis of Down syndrome and Alzheimer’s disease. All adults with Down syndrome will develop Alzheimer disease neuropathology by age 40 years. We have been involved in identifying neuronal networks that undergo significant degeneration in mouse models of Down syndrome and Alzheimer’s disease. Currently, my group is working on the role of norepinephrinergic system in failed contextual learning in the Ts65Dn mouse model of Down syndrome. We are hoping that improving this system would restore cognitive function in children and reduce the severity of Alzheimer pathology in adults with Down syndrome. In a double-blind placebo-controlled clinical trial, we are currently testing whether improved beta2 adrenergic signaling can improve cognitive function in individuals with mild to moderate dementia of Alzheimer type.